• Manisha Patel Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II Institutional Area, Greater Noida, Uttar Pradesh 201306, India https://orcid.org/0000-0002-0401-9644
  • RUPA MAZUMDER Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II Institutional Area, Greater Noida, Uttar Pradesh 201306, India https://orcid.org/0000-0002-1888-548X
  • Kamal Kant Kaushik Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II Institutional Area, Greater Noida, Uttar Pradesh 201306, India https://orcid.org/0000-0003-0082-5742
  • Abhijit Debnath Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II Institutional Area, Greater Noida, Uttar Pradesh 201306, India https://orcid.org/0000-0003-1056-1197
  • Rakhi Mishra Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II Institutional Area, Greater Noida, Uttar Pradesh 201306, India https://orcid.org/0000-0002-9292-3448
  • SHUBHAM PAL Noida Institute of Engineering and Technology (Pharmacy Institute), 19 Knowledge Park-II Institutional Area, Greater Noida, Uttar Pradesh 201306, India




COVID-19, Repurposed drug, Convalescent plasma therapy, Antiviral drug, Plasma therapy, Vaccination


A novel coronavirus disease, which is transmitted from human to human has quickly become the cause of the current worldwide health crisis. This virus is also known as SARS coronavirus belongs to the Coronaviridae family of viruses. The recent outbreak of acute respiratory disorders starting in Wuhan, China is found to be caused by this virus. The condition caused by it, known as COVID-19 has spread very rapidly all over the world causing so many death. This led WHO on Mar 11, 2020, to designate it as a global pandemic. An update on the history, etiology, epidemiology, pathophysiology and preventive methods for COVID-19 such as masking, quarantine, and social distancing are discussed in this paper. Repurposed drugs, antibodies, corticosteroids, vaccination and plasma transfusion are among the treatments explained in the study. Finally, the study discusses India’s COVID vaccination programme. The major aspects of this entire review are to describe COVID-19 infection, its prevention and treatment approach.


Download data is not yet available.


Ahmad Itoo F, Mohammad JM. Surfactant material properties and coronavirus surface: A surface interaction for covid-19 treatment and vaccination. Int J Chem Res. 2021 Oct;5(4):1-6.

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305-306.

Centers for Disease Control and Prevention. Clinical questions about COVID-19; 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq/ [Last accessed on 29 Mar 2022]

Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, Hellman J, Jog S, Kesecioglu J, Kissoon N, Martin-Loeches I, Nunnally ME, Prescott HC, Rhodes A, Talmor D, Tissieres P, De Backer D. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med. 2021 Apr 01;49(4):598-622.

Parthasarathy S, Sundararajan M, Manimaran A. Insights into corona/coronavirus disease 2019 pandemic- opinion versus evidence. Asian J Pharm Clin Res. 2021 Jul;14(7).

WHO. Severe-acute-respiratory-syndrome; Available from: https://www.who.int/health-topics/severe-acute-respiratory-syndrome/ [ Last accessed on 15 Mar 2022]

Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, Brichler S, Cohen Y. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020 Jun;55(6):106006.

Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020 Aug;43(4):328-333.

Stockman LJ, Massoudi MS, Helfand R, Erdman D, Siwek AM, Anderson LJ, Parashar UD. Severe acute respiratory syndrome in children. Pediatr Infect Dis J. 2007 Jan;26(1):68-74.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733.

Rauf A, Abu-Izneid T, Olatunde A, Ahmed Khalil A, Alhumaydhi FA, Tufail T, Shariati MA, Rebezov M, Almarhoon ZM, Mabkhot YN, Alsayari A, Rengasamy KRR. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int J Environ Res Public Health. 2020 Nov 4;17(21):8155.

Pan Y, Guan H. Imaging changes in patients with 2019-nCov. Eur Radiol. 2020 Jul;30(7):3612-3613.

Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020 Mar;83(3):217-220.

Shang Y, Li H, Zhang R. Effects of Pandemic Outbreak on Economies: Evidence from Business History Context. Front Public Health. 2021 Mar 12;9:632043.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207.

McIntosh K, Hirsch MS, Bloom A. COVID-19: Epidemiology, virology, and prevention. UpToDate. Available from: https://www.uptodate.com/contents/covid-19-epidemiology-virology-and-prevention [Last accessed on 18 Mar 2022]

WHO. Tracking SARS-CoV-2 variants; 2021. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ [Last accessed on 3 May 2022].

Ahmad FB, Cisewski JA, Miniño A, Anderson RN. Provisional Mortality Data - United States, 2020. MMWR Morb Mortal Wkly Rep. 2021 Apr 9;70(14):519-522.

Sharma AK, Naruka PS, Soni SL, Sharma V, Madaan V, Sharma M. COVID-19: A Review report, 2020. Int J Curr Pharm. 2022;14(1);17-22.

Cohen PA, Hall LE, John JN, Rapoport AB. The Early Natural History of SARS-CoV-2 Infection: Clinical Observations from an Urban, Ambulatory COVID-19 Clinic. Mayo Clin Proc. 2020 Jun;95(6):1124-1126.

WHO. Coronavirus disease (COVID-19); 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ [Last accessed on 15 Mar 2022].

Zhou G, Chen S, Chen Z. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies. Front Med. 2020 Apr;14(2):117-125.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 May;581(7807):215-220.

Lotfi R, Kalmarzi RN, Roghani SA. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Immunol Res. 2021 Jun;69(3):213-224.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.

Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005 Sep 16;309(5742):1864-8.

Colak H. Active and passive immunization against hepatitis B virus infection. Mikrobiyol Bul. 1982 Jan;16(1):71-6.

Jiang Z, Chen S, Zhu Q, Xiao Y, Qu J. COVID-19-associated pulmonary aspergillosis in a tertiary care center in Shenzhen City. J Infect Public Health. 2022 Feb;15(2):222-227.

Sukumaran S, Sathianarayanan S. A review on covid-19 pandemic a global threat-current status and challenges and preventive strategies. International Journal of Applied Pharmaceutics. 2021:10-14.

Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). 2022 Feb 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.

WHO. COVID-19 Dashboard. Available from: https://covid19.who.int/ [Last accessed on 21 Mar 2022]

Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R, Nishiura H. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med. 2020 Feb 17;9(2):538.

Marais C, Claude C, Semaan N, Charbel R, Barreault S, Travert B, Piloquet JE, Demailly Z, Morin L, Merchaoui Z, Teboul JL, Durand P, Miatello J, Tissières P; COVID-19 Immune Suppression (CLOVIS) Study Group. Myeloid phenotypes in severe COVID-19 predict secondary infection and mortality: a pilot study. Ann Intensive Care. 2021 Jul 14;11(1):111.

Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020 Oct 29;383(18):1757-1766.

Cherumanalil JM, Thayyil J. Pharmacological treatment of Covid-19 – A Review. Asian J Pharm Clin Res. 2020 Oct;13(10):16-22.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.

Ketkar H, Yang L, Wormser GP, Wang P. Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. Diagn Microbiol Infect Dis. 2019 Sep;95(1):38-40.

Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. J Clin Med. 2020 Jun 30;9(7):2050.

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020 Jun;92(6):556-563.

Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020 Mar 26;368:m1256.

Jose J, Babu JV, Mishra B. Convalescent plasma therapy: A novel approach to a novel coronavirus. Int J Pharm Pharm Sci. 2020 Aug;12(8):180-182.

Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020 Mar 16;14(1):69-71.

Mazhar F, Hadi MA, Kow CS, Marran AMN, Merchant HA, Hasan SS. Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. Int J Infect Dis. 2020 Dec;101:107-120.

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, Butterton JR, Johnson MG, De Anda C; MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022 Feb 10;386(6):509-520.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache JM, Bézie Y, Laplanche S, Le Berre A, Le Pavec J, Salmeron S, Emmerich J, Mourad JJ, Chatellier G, Hayem G. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020 Jul;2(7):e393-e400.

Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e01061-20.

Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, Hu M, Fang M, Gao Y. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020 Feb 21;5(1):18.

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.

Douedi S, Chaudhri M, Miskoff J. Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19. Ann Thorac Med. 2020 Jul-Sep;15(3):171-173.

Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O; Sarilumab COVID-19 Global Study Group. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 May;9(5):522-532.

Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021 Apr 22;384(16):1503-1516.

Mazumder S, Rastogi R, Undale A, Arora K, Arora NM, Pratim B, Kumar D, Joseph A, Mali B, Arya VB, Kalyanaraman S, Mukherjee A, Gupta A, Potdar S, Roy SS, Parashar D, Paliwal J, Singh SK, Naqvi A, Srivastava A, Singh MK, Kumar D, Bansal S, Rautray S, Saini M, Jain K, Gupta R, Kundu PK. A triple antigen virus-like particle vaccine candidate against SARS CoV-2. Heliyon. 2021 Oct;7(10):e08124;

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 Jun 2;16(6):1232-1238.

Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Front Microbiol. 2020 Feb 28;11:298.

Parums DV. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants. Med Sci Monit. 2022 Mar 1;28:e936523.

Ura T, Okuda K, Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines (Basel). 2014 Jul 29;2(3):624-41.

Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, Pan H, Wang X, Song Z, Wan J, Cui L, Li J, Chen Y, Wang X, Jin L, Liu J, Shi F, Xu X, Zhu T, Chen W, Zhu F. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022 Feb;28(2):401-409.

Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020 Oct 15;288:198114.

Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, Wang B, Chen C, Chen Y, Song X, Wang Y, Si W, Sun T, Wang X, Hou L, Chen W. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021 Dec;21(12):1654-1664.

Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014 Mar;22(3):668-674.

Bhatta M, Nandi S, Dutta S, Saha MK. Coronavirus (SARS-CoV-2): a systematic review for potential vaccines. Hum Vaccin Immunother. 2022 Dec 31;18(1):1865774.

Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. Cureus. 2020 May 28;12(5):e8342.

Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 Oct;586(7830):589-593.

Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 Dec 17;383(25):2439-2450.

Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021 May;97(1147):312-320.

Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Pawlicki J, Gillespie E, Maricic I, Zaidi FI, Kim KY, Dia Y, Frase D, Pezzoli P, Schultheis K, Smith TRF, Ramos SJ, McMullan T, Buttigieg K, Carroll MW, Ervin J, Diehl MC, Blackwood E, Mammen MP, Lee J, Dallas MJ, Brown AS, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021 Jan; 31:100689.

Yan ZP, Yang M, Lai CL. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals (Basel). 2021 Apr 25;14(5):406.

Kumari D, Prasad BD, Dwivedi P, Sahni S. COVID-19 Vaccines: A possible solution to ongoing pandemic. The Pharma Inno. 2021 Mar; 10(5): 1142-1145.

Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano. 2020 Oct 27;14(10):12522-12537.

Cowin. Wining over COVID-19; 2022. Available from: https://dashboard.cowin.gov.in/ [Last accessed on 5 May 2022]

Vaccinated India; 2022. Available from: https://vaccinate-india.in/dashboard/ [Last accessed on 5 May 2022]



How to Cite

PATEL, M., MAZUMDER, R., Kant Kaushik, K., DEBNATH, A., MISHRA, R., & PAL, S. (2022). A A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT. International Journal of Applied Pharmaceutics, 14(5). https://doi.org/10.22159/ijap.2022v14i5.45168



Review Article(s)